Semaglutide vs Tirzepatide
Semaglutide and Tirzepatide are the two most-studied GLP-1 research compounds in the recomposition category. This page compares their published specifications side by side. It does not rank them or make efficacy claims; the research overviews cover what the literature reports for each.
| Spec | Semaglutide | Tirzepatide |
|---|---|---|
| Category | Recomp | Recomp |
| CAS | 910463-68-2 | 2023788-19-2 |
| Formula | C₁₈₇H₂₉₁N₄₅O₅₉ | C₂₂₅H₃₄₈N₄₈O₆₈ |
| MW | 4113.58 g/mol | 4813.45 g/mol |
| Price | Sold out | Sold out |
| Research overview | Read → | Read → |
| Certificate of analysis | View → | View → |
| Product | View Semaglutide → | View Tirzepatide → |
Frequently asked
What is the difference between Semaglutide and Tirzepatide?
They are different research compounds with different peptide sequences, molecular weights, and CAS numbers, compared side by side in the table above. The mechanism and the published research for each is covered in its individual research overview, linked below.
Are Semaglutide and Tirzepatide both third-party tested?
Check the Certificate of analysis row above. A linked entry has a certificate in the public COA ledger. An entry marked No published COA is not presented as certified.
Are Semaglutide and Tirzepatide for human use?
No. Both are research compounds intended for laboratory and in-vitro research use only. Not for human consumption.
Which one should I research?
That depends on your research focus. Read each compound's research overview for what the literature reports, and if you are unsure, ask the research team on chat. We do not make the choice for you or provide dosing guidance.
For educational purposes only. Not medical advice. Research-use only. This comparison lists published specifications and does not rank the compounds or make efficacy claims. See our research disclaimer.